Company Profile
Celsus, Inc., a closely-held enterprise, was founded in 1987 to manufacture derivatives of crude heparin and to pursue the development of related complex carbohydrates belonging to the family of sulfated glycosaminoglycans for unmet medical and biomedical needs. The Company's tradename evokes the name of Aulus Cornelius Celsus, a first-century Roman medical encyclopedist.
Celsus Laboratories, Inc., a wholly-owned subsidiary company located in Cincinnati, is a USDA-approved, FDA-registered drug establishment that manufactures bulk-lyophilized heparin sodium of porcine tissue and various derivatives thereof.
Celsus Biopharmaceuticals, Inc, a wholly-owned subsidiary company, was founded in 1995 to develop a proprietary inhibitor of clot-bound thrombin and heparin cofactor II agonist. Its improved pharmacological profile makes it a preferable alternative to heparin in a variety of venous and arterial thrombo-embolic disorders, including states of heparin resistance and heparin-induced thrombocytopenia (HIT) where heparins are contraindicated.
Celsus BioMedical B.V., a wholly-owned subsidiary of Celsus, Inc. located in Maastricht was founded in 2008 to exploit new business opportunities in Europe and the Middle East.
Administrative Offices & Drug Establishment
12150 Best Place
Cincinnati, Ohio 45241-1569 USA
Phone (513) 772-8130 or (800) heparin Fax (513) 772-8132 or (888) heparin
Email inquiries@heparin.com
Directions
I-75 to exit 16, east on I-275 to exit 44, north on Mosteller Road, west on Crescentville Road, left onto Best Place.
History
The milestones in our history reflect a mission dedicated to the manufacture of heparin and the development of new complex carbohydrates for medical and biomedical needs unmet by heparin.
1987 - incorporation of Celsus Laboratories, Inc.1988 - introduction of a bulk-lyophilized Heparin Sodium USP
1989 - introduction of Heparin Lithium meeting NCCLS specifications
1990 - introduction of Heparin Ammonium and Heparin Calcium USP
1991 - completion of phase I clinical studies of ardeparin sodium
1992 - manufacture of commercial quantities of Dermatan Sulfate
1993 - introduction of bulk-lyophilized Heparin Zinc-Lithium for use in ABG syringes
1994 - introduction of Heparan Sulfate
1995 - discovery of Dermatan 4,6-O-Disulfate, a novel heparin cofactor II (HCII) agonist
1998 - move to a dedicated 15,000 sq.ft heparin production facility
1998 - validation of a bacterial endotoxin test using a kinetic chromogenic assay
1999 - first to introduce an immunoassay for the detection of prion antigens
2000 - process validated to eliminate infectious TSE
2001 - process validated to eliminate infectious viral impurities
2002 - discovery of targeted agents useful for diagnosis and therapy
2003 - discovery of synergy of a HCII-agonist with platelet IIb/IIIa receptor antagonists
2004 - doubled heparin production capacity to 400 billion units
2005 - first to discover an anticoagulant / antagonist of heparin-induced-thrombocytopenia
2006 - validation of a PCR method to determine animal origin by specie
2007 - first to manufacture commercial quantities of Enoxaparin Sodium in the U.S.
2008 - first to introduce a SAX-HPLC procedure to determine other polyanions in heparin